{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:35:13Z","timestamp":1783600513653,"version":"3.55.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Pujiang Program","award":["21PJD059"],"award-info":[{"award-number":["21PJD059"]}]},{"name":"Project of Shanghai Science and Technology Commission","award":["22ZR1451100"],"award-info":[{"award-number":["22ZR1451100"]}]},{"name":"Project of Shanghai Science and Technology Commission","award":["19140902900"],"award-info":[{"award-number":["19140902900"]}]},{"name":"Major Program of National Key Research and Development Project","award":["2020YFA0112600"],"award-info":[{"award-number":["2020YFA0112600"]}]},{"name":"Jiangxi Provincial Natural Science Foundation","award":["20212ACB206033"],"award-info":[{"award-number":["20212ACB206033"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173019"],"award-info":[{"award-number":["82173019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic\/Technology Research Leader","doi-asserted-by":"crossref","award":["20XD1434000"],"award-info":[{"award-number":["20XD1434000"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai"},{"name":"Shanghai Engineering Research Center of Stem Cells Translational Medicine","award":["20DZ2255100"],"award-info":[{"award-number":["20DZ2255100"]}]},{"name":"UNC School of Medicine, Chapel Hill, NC and by the Fibrolamellar Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s13402-022-00714-4","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T08:20:45Z","timestamp":1662798045000},"page":"1053-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Applications and mechanisms of the cyclin-dependent kinase 4\/6 inhibitor, PD-0332991, in solid tumors"],"prefix":"10.1007","volume":"45","author":[{"given":"Wenjian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"714_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"M. Malumbres, Cyclin-dependent kinases. Genome Biol. 15, 122 (2014). https:\/\/doi.org\/10.1186\/gb4184","journal-title":"Genome Biol."},{"key":"714_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tibs.2018.12.007","volume":"44","author":"P Icard","year":"2019","unstructured":"P. Icard, L. Fournel, Z. Wu, M. Alifano, H. Lincet, Interconnection between Metabolism and Cell Cycle in Cancer. Trends Biochem. Sci. 44, 490\u2013501 (2019). https:\/\/doi.org\/10.1016\/j.tibs.2018.12.007","journal-title":"Trends Biochem. Sci."},{"key":"714_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"S.R. Whittaker, A. Mallinger, P. Workman, P.A. Clarke, Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol. Ther. 173, 83\u2013105 (2017). https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.008","journal-title":"Pharmacol. Ther."},{"key":"714_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1101\/gad.11.7.847","volume":"11","author":"J LaBaer","year":"1997","unstructured":"J. LaBaer, M.D. Garrett, L.F. Stevenson, J.M. Slingerland, C. Sandhu, H.S. Chou, A. Fattaey, E. Harlow, New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847\u2013862 (1997). https:\/\/doi.org\/10.1101\/gad.11.7.847","journal-title":"Genes Dev."},{"key":"714_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/15216540701488358","volume":"59","author":"ET C\u00e1nepa","year":"2007","unstructured":"E.T. C\u00e1nepa, M.E. Scassa, J.M. Ceruti, M.C. Marazita, A.L. Carcagno, P.F. Sirkin, M.F. Ogara, INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59, 419\u2013426 (2007). https:\/\/doi.org\/10.1080\/15216540701488358","journal-title":"IUBMB Life"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1101\/gad.813200","volume":"14","author":"JW Harbour","year":"2000","unstructured":"J.W. Harbour, D.C. Dean, The Rb\/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14, 2393\u20132409 (2000). https:\/\/doi.org\/10.1101\/gad.813200","journal-title":"Genes Dev."},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W.R. Leopold, N.K. Pryer, P.L. Toogood, Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427\u20131438 (2004)","journal-title":"Mol. Cancer Ther."},{"key":"714_CR8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","volume":"66","author":"J Bollard","year":"2017","unstructured":"J. Bollard, V. Miguela, M. Ruiz de Galarreta, A. Venkatesh, C.B. Bian, M.P. Roberto, V. Tovar, D. Sia, P. Molina-Sanchez, C.B. Nguyen, S. Nakagawa, J.M. Llovet, Y. Hoshida, A. Lujambio, Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286\u20131296 (2017). https:\/\/doi.org\/10.1136\/gutjnl-2016-312268","journal-title":"Gut"},{"key":"714_CR9","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.Mct-10-0190","volume":"9","author":"C Albanese","year":"2010","unstructured":"C. Albanese, R. Alzani, N. Amboldi, N. Avanzi, D. Ballinari, M.G. Brasca, C. Festuccia, F. Fiorentini, G. Locatelli, W. Pastori, V. Patton, F. Roletto, F. Colotta, A. Galvani, A. Isacchi, J. Moll, E. Pesenti, C. Mercurio, M. Ciomei, Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol. Cancer Ther. 9, 2243\u20132254 (2010). https:\/\/doi.org\/10.1158\/1535-7163.Mct-10-0190","journal-title":"Mol. Cancer Ther."},{"key":"714_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.10738","volume":"102","author":"SJ McClue","year":"2002","unstructured":"S.J. McClue, D. Blake, R. Clarke, A. Cowan, L. Cummings, P.M. Fischer, M. MacKenzie, J. Melville, K. Stewart, S. Wang, N. Zhelev, D. Zheleva, D.P. Lane, In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463\u2013468 (2002). https:\/\/doi.org\/10.1002\/ijc.10738","journal-title":"Int. J. Cancer"},{"key":"714_CR11","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1158\/1535-7163.Mct-12-0286","volume":"11","author":"G Siemeister","year":"2012","unstructured":"G. Siemeister, U. L\u00fccking, A.M. Wengner, P. Lienau, W. Steinke, C. Schatz, D. Mumberg, K. Ziegelbauer, BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol. Cancer Ther. 11, 2265\u20132273 (2012). https:\/\/doi.org\/10.1158\/1535-7163.Mct-12-0286","journal-title":"Mol. Cancer Ther."},{"key":"714_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s1040-8428(00)00124-4","volume":"38","author":"HH Sedlacek","year":"2001","unstructured":"H.H. Sedlacek, Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38, 139\u2013170 (2001). https:\/\/doi.org\/10.1016\/s1040-8428(00)00124-4","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"714_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J.G. Delcros, J.P. Moulinoux, Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527\u2013536 (1997). https:\/\/doi.org\/10.1111\/j.1432-1033.1997.t01-2-00527.x","journal-title":"Eur. J. Biochem."},{"key":"714_CR14","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","volume":"64","author":"KD Freeman-Cook","year":"2021","unstructured":"K.D. Freeman-Cook, R.L. Hoffman, D.C. Behenna, B. Boras, J. Carelli, W. Diehl, R.A. Ferre, Y.A. He, A. Hui, B. Huang, N. Huser, R. Jones, S.E. Kephart, J. Lapek, M. McTigue, N. Miller, B.W. Murray, A. Nagata, L. Nguyen, S. Niessen, S. Ninkovic, I. O\u2019Doherty, M.A. Ornelas, J. Solowiej, S.C. Sutton, K. Tran, E. Tseng, R. Visswanathan, M. Xu, L. Zehnder, Q. Zhang, C. Zhang, S. Dann, Discovery of PF-06873600, a CDK2\/4\/6 Inhibitor for the treatment of cancer. J. Med. Chem. 64, 9056\u20139077 (2021). https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00159","journal-title":"J. Med. Chem."},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"e0234103","DOI":"10.1371\/journal.pone.0234103","volume":"15","author":"S Frame","year":"2020","unstructured":"S. Frame, C. Saladino, C. MacKay, B. Atrash, P. Sheldrake, E. McDonald, P.A. Clarke, P. Workman, D. Blake, D. Zheleva, Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One 15, e0234103 (2020). https:\/\/doi.org\/10.1371\/journal.pone.0234103","journal-title":"PLoS One"},{"key":"714_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1158\/0008-5472.Can-05-1769","volume":"66","author":"D Cai","year":"2006","unstructured":"D. Cai, K.F. Byth, G.I. Shapiro, AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res. 66, 435\u2013444 (2006). https:\/\/doi.org\/10.1158\/0008-5472.Can-05-1769","journal-title":"Cancer Res."},{"key":"714_CR17","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.0600447103","volume":"103","author":"LT Vassilev","year":"2006","unstructured":"L.T. Vassilev, C. Tovar, S. Chen, D. Knezevic, X. Zhao, H. Sun, D.C. Heimbrook, L. Chen, Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U. S. A. 103, 10660\u201310665 (2006). https:\/\/doi.org\/10.1073\/pnas.0600447103","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"714_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.281.5376.533","volume":"281","author":"NS Gray","year":"1998","unstructured":"N.S. Gray, L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, F.H. Espinoza, D.O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S.H. Kim, D.J. Lockhart, P.G. Schultz, Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533\u2013538 (1998). https:\/\/doi.org\/10.1126\/science.281.5376.533","journal-title":"Science"},{"key":"714_CR19","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1021\/jm0311442","volume":"47","author":"IR Hardcastle","year":"2004","unstructured":"I.R. Hardcastle, C.E. Arris, J. Bentley, F.T. Boyle, Y. Chen, N.J. Curtin, J.A. Endicott, A.E. Gibson, B.T. Golding, R.J. Griffin, P. Jewsbury, J. Menyerol, V. Mesguiche, D.R. Newell, M.E. Noble, D.J. Pratt, L.Z. Wang, H.J. Whitfield, N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem. 47, 3710\u20133722 (2004). https:\/\/doi.org\/10.1021\/jm0311442","journal-title":"J. Med. Chem."},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.bjc.6605479","volume":"102","author":"N Johnson","year":"2010","unstructured":"N. Johnson, J. Bentley, L.Z. Wang, D.R. Newell, C.N. Robson, G.I. Shapiro, N.J. Curtin, Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br. J. Cancer 102, 342\u2013350 (2010). https:\/\/doi.org\/10.1038\/sj.bjc.6605479","journal-title":"Br. J. Cancer"},{"key":"714_CR21","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","volume":"113","author":"R Chen","year":"2009","unstructured":"R. Chen, W.G. Wierda, S. Chubb, R.E. Hawtin, J.A. Fox, M.J. Keating, V. Gandhi, W. Plunkett, Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113, 4637\u20134645 (2009). https:\/\/doi.org\/10.1182\/blood-2008-12-190256","journal-title":"Blood"},{"key":"714_CR22","doi-asserted-by":"publisher","first-page":"13865","DOI":"10.1002\/anie.202004087","volume":"59","author":"M Teng","year":"2020","unstructured":"M. Teng, J. Jiang, Z. He, N.P. Kwiatkowski, K.A. Donovan, C.E. Mills, C. Victor, J.M. Hatcher, E.S. Fischer, P.K. Sorger, T. Zhang, N.S. Gray, Development of CDK2 and CDK5 dual degrader TMX-2172. Angew Chem. Int. Ed. Engl. 59, 13865\u201313870 (2020). https:\/\/doi.org\/10.1002\/anie.202004087","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"714_CR23","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1158\/1078-0432.Ccr-13-1675","volume":"19","author":"J Rader","year":"2013","unstructured":"J. Rader, M.R. Russell, L.S. Hart, M.S. Nakazawa, L.T. Belcastro, D. Martinez, Y. Li, E.L. Carpenter, E.F. Attiyeh, S.J. Diskin, S. Kim, S. Parasuraman, G. Caponigro, R.W. Schnepp, A.C. Wood, B. Pawel, K.A. Cole, J.M. Maris, Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res. 19, 6173\u20136182 (2013). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-1675","journal-title":"Clin. Cancer Res."},{"key":"714_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"L.M. Gelbert, S. Cai, X. Lin, C. Sanchez-Martinez, M. Del Prado, M.J. Lallena, R. Torres, R.T. Ajamie, G.N. Wishart, R.S. Flack, B.L. Neubauer, J. Young, E.M. Chan, P. Iversen, D. Cronier, E. Kreklau, A. de Dios, Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs 32, 825\u2013837 (2014). https:\/\/doi.org\/10.1007\/s10637-014-0120-7","journal-title":"Invest New Drugs"},{"key":"714_CR25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.Mct-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"H. Patel, M. Periyasamy, G.P. Sava, A. Bondke, B.W. Slafer, S.H.B. Kroll, M. Barbazanges, R. Starkey, S. Ottaviani, A. Harrod, E.O. Aboagye, L. Buluwela, M.J. Fuchter, A.G.M. Barrett, R.C. Coombes, S. Ali, ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol. Cancer Ther. 17, 1156\u20131166 (2018). https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0847","journal-title":"Mol. Cancer Ther."},{"key":"714_CR26","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/0008-5472.Can-19-0119","volume":"79","author":"S Hu","year":"2019","unstructured":"S. Hu, J.J. Marineau, N. Rajagopal, K.B. Hamman, Y.J. Choi, D.R. Schmidt, N. Ke, L. Johannessen, M.J. Bradley, D.A. Orlando, S.R. Alnemy, Y. Ren, S. Ciblat, D.K. Winter, A. Kabro, K.T. Sprott, J.G. Hodgson, C.C. Fritz, J.P. Carulli, E. di Tomaso, E.R. Olson, Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 79, 3479\u20133491 (2019). https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0119","journal-title":"Cancer Res."},{"key":"714_CR27","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1158\/0008-5472.can-06-3437","volume":"67","author":"MR Ramsey","year":"2007","unstructured":"M.R. Ramsey, J. Krishnamurthy, X.H. Pei, C. Torrice, W. Lin, D.R. Carrasco, K.L. Ligon, Y. Xiong, N.E. Sharpless, Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4\/6-dependent tumors and tissues. Cancer Res. 67, 4732\u20134741 (2007). https:\/\/doi.org\/10.1158\/0008-5472.can-06-3437","journal-title":"Cancer Res."},{"key":"714_CR28","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/1535-7163.MCT-14-0793","volume":"14","author":"G Eilers","year":"2015","unstructured":"G. Eilers, J.T. Czaplinski, M. Mayeda, N. Bahri, D. Tao, M. Zhu, J.L. Hornick, N.I. Lindeman, E. Sicinska, A.J. Wagner, J.A. Fletcher, A. Marino-Enriquez, CDKN2A\/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Mol. Cancer Ther. 14, 1346\u20131353 (2015). https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0793","journal-title":"Mol. Cancer Ther."},{"key":"714_CR29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/neuonc\/nos114","volume":"14","author":"L Cen","year":"2012","unstructured":"L. Cen, B.L. Carlson, M.A. Schroeder, J.L. Ostrem, G.J. Kitange, A.C. Mladek, S.R. Fink, P.A. Decker, W. Wu, J.S. Kim, T. Waldman, R.B. Jenkins, J.N. Sarkaria, p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 14, 870\u2013881 (2012). https:\/\/doi.org\/10.1093\/neuonc\/nos114","journal-title":"Neuro Oncol."},{"key":"714_CR30","doi-asserted-by":"publisher","first-page":"15788","DOI":"10.18632\/oncotarget.3819","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"A.K. Witkiewicz, N.A. Borja, J. Franco, J.R. Brody, C.J. Yeo, J. Mansour, M.A. Choti, P. McCue, E.S. Knudsen, Selective impact of CDK4\/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 6, 15788\u201315801 (2015). https:\/\/doi.org\/10.18632\/oncotarget.3819","journal-title":"Oncotarget"},{"key":"714_CR31","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/0008-5472.CAN-15-3384","volume":"76","author":"JL Teh","year":"2016","unstructured":"J.L. Teh, T.J. Purwin, E.J. Greenawalt, I. Chervoneva, A. Goldberg, M.A. Davies, A.E. Aplin, An in vivo reporter to quantitatively and temporally analyze the effects of CDK4\/6 inhibitor-based therapies in Melanoma. Cancer Res. 76, 5455\u20135466 (2016). https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3384","journal-title":"Cancer Res."},{"key":"714_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","volume":"15","author":"A Nemoto","year":"2016","unstructured":"A. Nemoto, S. Saida, I. Kato, J. Kikuchi, Y. Furukawa, Y. Maeda, K. Akahane, H. Honna-Oshiro, K. Goi, K. Kagami, S. Kimura, Y. Sato, S. Okabe, A. Niwa, K. Watanabe, T. Nakahata, T. Heike, K. Sugita, T. Inukai, Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia. Mol. Cancer Ther. 15, 94\u2013105 (2016). https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1065","journal-title":"Mol. Cancer Ther."},{"key":"714_CR33","doi-asserted-by":"publisher","first-page":"8710","DOI":"10.1073\/pnas.1117255109","volume":"109","author":"E Huillard","year":"2012","unstructured":"E. Huillard, R. Hashizume, J.J. Phillips, A. Griveau, R.A. Ihrie, Y. Aoki, T. Nicolaides, A. Perry, T. Waldman, M. McMahon, W.A. Weiss, C. Petritsch, C.D. James, D.H. Rowitch, Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc. Natl. Acad. Sci. U. S. A. 109, 8710\u20138715 (2012). https:\/\/doi.org\/10.1073\/pnas.1117255109","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"714_CR34","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1053\/j.gastro.2010.01.007","volume":"138","author":"DB Rivadeneira","year":"2010","unstructured":"D.B. Rivadeneira, C.N. Mayhew, C. Thangavel, E. Sotillo, C.A. Reed, X. Grana, E.S. Knudsen, Proliferative suppression by CDK4\/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 138, 1920\u20131930 (2010). https:\/\/doi.org\/10.1053\/j.gastro.2010.01.007","journal-title":"Gastroenterology"},{"key":"714_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O'Leary","year":"2016","unstructured":"B. O\u2019Leary, R.S. Finn, N.C. Turner, Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016). https:\/\/doi.org\/10.1038\/nrclinonc.2016.26","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"714_CR36","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-15-2347","volume":"76","author":"M Acevedo","year":"2016","unstructured":"M. Acevedo, M. Vernier, L. Mignacca, F. Lessard, G. Huot, O. Moiseeva, V. Bourdeau, G. Ferbeyre, A CDK4\/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 76, 3252\u20133264 (2016). https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2347","journal-title":"Cancer Res."},{"key":"714_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"A. Hernandez-Segura, J. Nehme, M. Demaria, Hallmarks of cellular senescence. Trends Cell Biol. 28, 436\u2013453 (2018). https:\/\/doi.org\/10.1016\/j.tcb.2018.02.001","journal-title":"Trends Cell Biol."},{"key":"714_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fendo.2017.00311","volume":"8","author":"PD Denechaud","year":"2017","unstructured":"P.D. Denechaud, L. Fajas, A. Giralt, E2F1, a Novel Regulator of Metabolism. Front Endocrinol. (Lausanne) 8, 311 (2017). https:\/\/doi.org\/10.3389\/fendo.2017.00311","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"714_CR39","doi-asserted-by":"publisher","first-page":"107504","DOI":"10.1016\/j.celrep.2020.03.068","volume":"31","author":"J Romero-Pozuelo","year":"2020","unstructured":"J. Romero-Pozuelo, G. Figlia, O. Kaya, A. Martin-Villalba, A.A. Teleman, Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1. Cell Rep. 31, 107504 (2020). https:\/\/doi.org\/10.1016\/j.celrep.2020.03.068","journal-title":"Cell Rep."},{"key":"714_CR40","doi-asserted-by":"publisher","first-page":"108944","DOI":"10.1016\/j.celrep.2021.108944","volume":"35","author":"RV Uzhachenko","year":"2021","unstructured":"R.V. Uzhachenko, V. Bharti, Z. Ouyang, A. Blevins, S. Mont, N. Saleh, H.A. Lawrence, C. Shen, S.C. Chen, G.D. Ayers, D.G. DeNardo, C. Arteaga, A. Richmond, A.E. Vilgelm, Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 35, 108944 (2021). https:\/\/doi.org\/10.1016\/j.celrep.2021.108944","journal-title":"Cell Rep."},{"key":"714_CR41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.Ccr-17-2074","volume":"24","author":"C Thangavel","year":"2018","unstructured":"C. Thangavel, E. Boopathi, Y. Liu, C. McNair, A. Haber, M. Perepelyuk, A. Bhardwaj, S. Addya, A. Ertel, S. Shoyele, R. Birbe, J.M. Salvino, A.P. Dicker, K.E. Knudsen, R.B. Den, Therapeutic challenge with a CDK 4\/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non-small cell lung cancer. Clin. Cancer Res. 24, 1402\u20131414 (2018). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2074","journal-title":"Clin. Cancer Res."},{"key":"714_CR42","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/bph.13836","volume":"174","author":"L Chen","year":"2017","unstructured":"L. Chen, J. Pan, Dual cyclin-dependent kinase 4\/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br. J. Pharmacol. 174, 2427\u20132443 (2017). https:\/\/doi.org\/10.1111\/bph.13836","journal-title":"Br. J. Pharmacol."},{"key":"714_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bcp.2019.02.017","volume":"163","author":"G Zhang","year":"2019","unstructured":"G. Zhang, F. Ma, L. Li, J. Li, P. Li, S. Zeng, H. Sun, E. Li, Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex. Biochem. Pharmacol. 163, 133\u2013141 (2019). https:\/\/doi.org\/10.1016\/j.bcp.2019.02.017","journal-title":"Biochem. Pharmacol."},{"key":"714_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2018.07.010","volume":"102","author":"CY Huang","year":"2018","unstructured":"C.Y. Huang, F.S. Hsieh, C.Y. Wang, L.J. Chen, S.S. Chang, M.H. Tsai, M.H. Hung, C.W. Kuo, C.T. Shih, T.I. Chao, K.F. Chen, Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur. J. Cancer 102, 10\u201322 (2018). https:\/\/doi.org\/10.1016\/j.ejca.2018.07.010","journal-title":"Eur. J. Cancer"},{"key":"714_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm3591","volume":"14","author":"TH Cheung","year":"2013","unstructured":"T.H. Cheung, T.A. Rando, Molecular regulation of stem cell quiescence. Nature reviews. Mol. Cell Biol. 14, 329\u2013340 (2013). https:\/\/doi.org\/10.1038\/nrm3591","journal-title":"Mol. Cell Biol."},{"key":"714_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/15384101.2020.1859195","volume":"20","author":"RS Maskey","year":"2021","unstructured":"R.S. Maskey, F. Wang, E. Lehman, Y. Wang, N. Emmanuel, W. Zhong, G. Jin, R.T. Abraham, K.T. Arndt, J.S. Myers, A. Mazurek, Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle 20, 65\u201380 (2021). https:\/\/doi.org\/10.1080\/15384101.2020.1859195","journal-title":"Cell Cycle"},{"key":"714_CR47","doi-asserted-by":"publisher","first-page":"aaf4445-1","DOI":"10.1126\/science.aaf4445","volume":"354","author":"L Mosteiro","year":"2016","unstructured":"L. Mosteiro, C. Pantoja, N. Alcazar, R.M. Marion, D. Chondronasiou, M. Rovira, P.J. Fernandez-Marcos, M. Munoz-Martin, C. Blanco-Aparicio, J. Pastor, G. Gomez-Lopez, A. De Martino, M.A. Blasco, M. Abad, M. Serrano, Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science 354, aaf4445 (2016). https:\/\/doi.org\/10.1126\/science.aaf4445","journal-title":"Science"},{"key":"714_CR48","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"R.A. Saxton, D.M. Sabatini, mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017). https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"714_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41556-018-0244-7","volume":"21","author":"RE Lawrence","year":"2019","unstructured":"R.E. Lawrence, R. Zoncu, The lysosome as a cellular centre for signalling, metabolism and quality control. Nat. Cell Biol. 21, 133\u2013142 (2019). https:\/\/doi.org\/10.1038\/s41556-018-0244-7","journal-title":"Nat. Cell Biol."},{"key":"714_CR50","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","volume":"25","author":"CC Dibble","year":"2015","unstructured":"C.C. Dibble, L.C. Cantley, Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 25, 545\u2013555 (2015). https:\/\/doi.org\/10.1016\/j.tcb.2015.06.002","journal-title":"Trends Cell Biol."},{"key":"714_CR51","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s42255-021-00483-8","volume":"3","author":"CD Wiley","year":"2021","unstructured":"C.D. Wiley, J. Campisi, The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat. Metab. 3, 1290\u20131301 (2021). https:\/\/doi.org\/10.1038\/s42255-021-00483-8","journal-title":"Nat. Metab."},{"key":"714_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","volume":"479","author":"TW Kang","year":"2011","unstructured":"T.W. Kang, T. Yevsa, N. Woller, L. Hoenicke, T. Wuestefeld, D. Dauch, A. Hohmeyer, M. Gereke, R. Rudalska, A. Potapova, M. Iken, M. Vucur, S. Weiss, M. Heikenwalder, S. Khan, J. Gil, D. Bruder, M. Manns, P. Schirmacher, F. Tacke, M. Ott, T. Luedde, T. Longerich, S. Kubicka, L. Zender, Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547\u2013551 (2011). https:\/\/doi.org\/10.1038\/nature10599","journal-title":"Nature"},{"key":"714_CR53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"M. Milanovic, D.N.Y. Fan, D. Belenki, J.H.M. Dabritz, Z. Zhao, Y. Yu, J.R. Dorr, L. Dimitrova, D. Lenze, I.A. Monteiro Barbosa, M.A. Mendoza-Parra, T. Kanashova, M. Metzner, K. Pardon, M. Reimann, A. Trumpp, B. Dorken, J. Zuber, H. Gronemeyer, M. Hummel, G. Dittmar, S. Lee, C.A. Schmitt, Senescence-associated reprogramming promotes cancer stemness. Nature 553, 96\u2013100 (2018). https:\/\/doi.org\/10.1038\/nature25167","journal-title":"Nature"},{"key":"714_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","volume":"30","author":"T Eggert","year":"2016","unstructured":"T. Eggert, K. Wolter, J. Ji, C. Ma, T. Yevsa, S. Klotz, J. Medina-Echeverz, T. Longerich, M. Forgues, F. Reisinger, M. Heikenwalder, X.W. Wang, L. Zender, T.F. Greten, Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell 30, 533\u2013547 (2016). https:\/\/doi.org\/10.1016\/j.ccell.2016.09.003","journal-title":"Cancer Cell"},{"key":"714_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"B.A. Carneiro, W.S. El-Deiry, Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 17, 395\u2013417 (2020). https:\/\/doi.org\/10.1038\/s41571-020-0341-y","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"714_CR56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","volume":"14","author":"Z Su","year":"2015","unstructured":"Z. Su, Z. Yang, Y. Xu, Y. Chen, Q. Yu, Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol. Cancer 14, 48 (2015). https:\/\/doi.org\/10.1186\/s12943-015-0321-5","journal-title":"Mol. Cancer"},{"key":"714_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/mc.22771","volume":"57","author":"DR Premkumar","year":"2018","unstructured":"D.R. Premkumar, E.P. Jane, S. Thambireddy, P.A. Sutera, J.M. Cavaleri, I.F. Pollack, Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells. Mol. Carcinog. 57, 469\u2013482 (2018). https:\/\/doi.org\/10.1002\/mc.22771","journal-title":"Mol. Carcinog."},{"key":"714_CR58","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","volume":"22","author":"YJ Choi","year":"2012","unstructured":"Y.J. Choi, X. Li, P. Hydbring, T. Sanda, J. Stefano, A.L. Christie, S. Signoretti, A.T. Look, A.L. Kung, H. von Boehmer, P. Sicinski, The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438\u2013451 (2012). https:\/\/doi.org\/10.1016\/j.ccr.2012.09.015","journal-title":"Cancer Cell"},{"key":"714_CR59","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","volume":"133","author":"BM Grande","year":"2019","unstructured":"B.M. Grande, D.S. Gerhard, A. Jiang, N.B. Griner, J.S. Abramson, T.B. Alexander, H. Allen, L.W. Ayers, J.M. Bethony, K. Bhatia, J. Bowen, C. Casper, J.K. Choi, L. Culibrk, T.M. Davidsen, M.A. Dyer, J.M. Gastier-Foster, P. Gesuwan, T.C. Greiner, T.G. Gross, B. Hanf, N.L. Harris, Y. He, J.D. Irvin, E.S. Jaffe, S.J.M. Jones, P. Kerchan, N. Knoetze, F.E. Leal, T.M. Lichtenberg, Y. Ma, J.P. Martin, M.R. Martin, S.M. Mbulaiteye, C.G. Mullighan, A.J. Mungall, C. Namirembe, K. Novik, A. Noy, M.D. Ogwang, A. Omoding, J. Orem, S.J. Reynolds, C.K. Rushton, J.T. Sandlund, R. Schmitz, C. Taylor, W.H. Wilson, G.W. Wright, E.Y. Zhao, M.A. Marra, R.D. Morin, L.M. Staudt, Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 133, 1313\u20131324 (2019). https:\/\/doi.org\/10.1182\/blood-2018-09-871418","journal-title":"Blood"},{"key":"714_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ceb.2014.10.006","volume":"33","author":"IC Lopez-Mejia","year":"2015","unstructured":"I.C. Lopez-Mejia, L. Fajas, Cell cycle regulation of mitochondrial function. Curr. Opin. Cell Biol. 33, 19\u201325 (2015). https:\/\/doi.org\/10.1016\/j.ceb.2014.10.006","journal-title":"Curr. Opin. Cell Biol."},{"key":"714_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.chembiol.2017.12.010","volume":"25","author":"B Warth","year":"2018","unstructured":"B. Warth, P. Raffeiner, A. Granados, T. Huan, M. Fang, E.M. Forsberg, H.P. Benton, L. Goetz, C.H. Johnson, G. Siuzdak, Metabolomics reveals that dietary xenoestrogens alter cellular metabolism induced by Palbociclib\/Letrozole combination cancer therapy. Cell Chem. Biol. 25, 291-300.e293 (2018). https:\/\/doi.org\/10.1016\/j.chembiol.2017.12.010","journal-title":"Cell Chem. Biol."},{"key":"714_CR62","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.3390\/ijms21145165","volume":"21","author":"M Bonelli","year":"2020","unstructured":"M. Bonelli, R. Terenziani, S. Zoppi, C. Fumarola, S. La Monica, D. Cretella, R. Alfieri, A. Cavazzoni, G. Digiacomo, M. Galetti, P.G. Petronini, Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR signaling impairs energy metabolism in MPM cancer cells. Int. J. Mol. Sci. 21, 5165 (2020). https:\/\/doi.org\/10.3390\/ijms21145165","journal-title":"Int. J. Mol. Sci."},{"key":"714_CR63","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jcb.29249","volume":"121","author":"O Rencuzogullari","year":"2020","unstructured":"O. Rencuzogullari, P.O. Yerlikaya, A.C. Gurkan, E.D. Arisan, D. Telci, Palbociclib, a selective CDK4\/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. J. Cell Biochem. 121, 508\u2013523 (2020). https:\/\/doi.org\/10.1002\/jcb.29249","journal-title":"J. Cell Biochem."},{"key":"714_CR64","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1038\/onc.2017.120","volume":"36","author":"M Pek","year":"2017","unstructured":"M. Pek, S. Yatim, Y. Chen, J. Li, M. Gong, X. Jiang, F. Zhang, J. Zheng, X. Wu, Q. Yu, Oncogenic KRAS-associated gene signature defines co-targeting of CDK4\/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene 36, 4975\u20134986 (2017). https:\/\/doi.org\/10.1038\/onc.2017.120","journal-title":"Oncogene"},{"key":"714_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.09.027","volume":"411","author":"X Zhou","year":"2017","unstructured":"X. Zhou, J. Chen, L. Chen, X. Feng, Z. Liu, Z. Hu, X. Zeng, M. Jia, B. Liang, G.. Yi. Shi, J. Liu, Negative regulation of Sirtuin 1 by AMP-activated protein kinase promotes metformin-induced senescence in hepatocellular carcinoma xenografts. Cancer Lett. 411, 1\u201311 (2017). https:\/\/doi.org\/10.1016\/j.canlet.2017.09.027","journal-title":"Cancer Lett."},{"key":"714_CR66","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/1878-0261.12072","volume":"11","author":"FS Hsieh","year":"2017","unstructured":"F.S. Hsieh, Y.L. Chen, M.H. Hung, P.Y. Chu, M.H. Tsai, L.J. Chen, Y.J. Hsiao, C.T. Shih, M.J. Chang, T.I. Chao, C.W. Shiau, K.F. Chen, Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4\/6-independent manner. Mol. Oncol. 11, 1035\u20131049 (2017). https:\/\/doi.org\/10.1002\/1878-0261.12072","journal-title":"Mol. Oncol."},{"key":"714_CR67","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/0008-5472.CAN-14-2486","volume":"75","author":"C Yang","year":"2015","unstructured":"C. Yang, C.A. Boyson, M. Di Liberto, X. Huang, J. Hannah, D.C. Dorn, M.A. Moore, S. Chen-Kiang, P. Zhou, CDK4\/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res. 75, 1838\u20131845 (2015). https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2486","journal-title":"Cancer Res."},{"key":"714_CR68","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"A.A. Samatar, P.I. Poulikakos, Targeting RAS-ERK signalling in cancer: promises and challenges. Nature reviews. Drug Discov. 13, 928\u2013942 (2014). https:\/\/doi.org\/10.1038\/nrd4281","journal-title":"Drug Discov."},{"key":"714_CR69","doi-asserted-by":"publisher","first-page":"39595","DOI":"10.18632\/oncotarget.9153","volume":"7","author":"MS Lee","year":"2016","unstructured":"M.S. Lee, T.L. Helms, N. Feng, J. Gay, Q.E. Chang, F. Tian, J.Y. Wu, C. Toniatti, T.P. Heffernan, G. Powis, L.N. Kwong, S. Kopetz, Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 7, 39595\u201339608 (2016). https:\/\/doi.org\/10.18632\/oncotarget.9153","journal-title":"Oncotarget"},{"key":"714_CR70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/1078-0432.CCR-15-0829","volume":"22","author":"EK Ziemke","year":"2016","unstructured":"E.K. Ziemke, J.S. Dosch, J.D. Maust, A. Shettigar, A. Sen, T.H. Welling, K.M. Hardiman, J.S. Sebolt-Leopold, Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4\/6. Clin. Cancer Res. 22, 405\u2013414 (2016). https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0829","journal-title":"Clin. Cancer Res."},{"key":"714_CR71","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2017.08.031","volume":"408","author":"J Zhou","year":"2017","unstructured":"J. Zhou, S. Zhang, X. Chen, X. Zheng, Y. Yao, G. Lu, J. Zhou, Palbociclib, a selective CDK4\/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer. Cancer Lett. 408, 130\u2013137 (2017). https:\/\/doi.org\/10.1016\/j.canlet.2017.08.031","journal-title":"Cancer Lett."},{"key":"714_CR72","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1530\/ERC-19-0011","volume":"26","author":"K Wong","year":"2019","unstructured":"K. Wong, F. Di Cristofano, M. Ranieri, D. De Martino, A. Di Cristofano, PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer. Endocr. Relat. Cancer 26, 425\u2013436 (2019). https:\/\/doi.org\/10.1530\/ERC-19-0011","journal-title":"Endocr. Relat. Cancer"},{"key":"714_CR73","doi-asserted-by":"publisher","first-page":"563249","DOI":"10.3389\/fonc.2020.563249","volume":"10","author":"G Digiacomo","year":"2020","unstructured":"G. Digiacomo, C. Fumarola, S. La Monica, M.A. Bonelli, D. Cretella, R. Alfieri, A. Cavazzoni, M. Galetti, P. Bertolini, G. Missale, P.G. Petronini, Simultaneous combination of the CDK4\/6 inhibitor palbociclib with regorafenib induces enhanced anti-tumor effects in hepatocarcinoma cell lines. Front Oncol. 10, 563249 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.563249","journal-title":"Front Oncol."},{"key":"714_CR74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1078-0432.Ccr-18-0284","volume":"25","author":"X Song","year":"2019","unstructured":"X. Song, X. Liu, H. Wang, J. Wang, Y. Qiao, A. Cigliano, K. Utpatel, S. Ribback, M.G. Pilo, M. Serra, J.D. Gordan, L. Che, S. Zhang, A. Cossu, A. Porcu, R.M. Pascale, F. Dombrowski, H. Hu, D.F. Calvisi, M. Evert, X. Chen, Combined CDK4\/6 and Pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin. Cancer Res. 25, 403\u2013413 (2019). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0284","journal-title":"Clin. Cancer Res."},{"key":"714_CR75","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","volume":"22","author":"S Loibl","year":"2017","unstructured":"S. Loibl, N.C. Turner, J. Ro, M. Cristofanilli, H. Iwata, S.A. Im, N. Masuda, S. Loi, F. Andr\u00e9, N. Harbeck, S. Verma, E. Folkerd, K. Puyana Theall, J. Hoffman, K. Zhang, C.H. Bartlett, M. Dowsett, Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist 22, 1028\u20131038 (2017). https:\/\/doi.org\/10.1634\/theoncologist.2017-0072","journal-title":"Oncologist"},{"key":"714_CR76","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"N.C. Turner, J. Ro, F. Andr\u00e9, S. Loi, S. Verma, H. Iwata, N. Harbeck, S. Loibl, C. Huang Bartlett, K. Zhang, C. Giorgetti, S. Randolph, M. Koehler, M. Cristofanilli, Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209\u2013219 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1505270","journal-title":"N. Engl. J. Med."},{"key":"714_CR77","doi-asserted-by":"publisher","first-page":"djv212-1","DOI":"10.1093\/jnci\/djv212","volume":"107","author":"SR Johnston","year":"2015","unstructured":"S.R. Johnston, Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J. Natl. Cancer Inst. 107, djv212 (2015). https:\/\/doi.org\/10.1093\/jnci\/djv212","journal-title":"J. Natl. Cancer Inst."},{"key":"714_CR78","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1535-7163.MCT-17-0040","volume":"16","author":"AM Francis","year":"2017","unstructured":"A.M. Francis, A. Alexander, Y. Liu, S. Vijayaraghavan, K.H. Low, D. Yang, T. Bui, N. Somaiah, V. Ravi, K. Keyomarsi, K.K. Hunt, CDK4\/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell-cycle arrest. Mol. Cancer Ther. 16, 1751\u20131764 (2017). https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0040","journal-title":"Mol. Cancer Ther."},{"key":"714_CR79","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1535-7163.MCT-19-0162","volume":"18","author":"T Kong","year":"2019","unstructured":"T. Kong, Y. Xue, R. Cencic, X. Zhu, A. Monast, Z. Fu, V. Pilon, V. Sangwan, M.C. Guiot, W.D. Foulkes, J.A. Porco Jr., M. Park, J. Pelletier, S. Huang, eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4\/6 inhibition in cancer. Mol. Cancer Ther. 18, 2158\u20132170 (2019). https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0162","journal-title":"Mol. Cancer Ther."},{"key":"714_CR80","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.celrep.2020.02.002","volume":"30","author":"J Chu","year":"2020","unstructured":"J. Chu, W. Zhang, R. Cencic, P.B.F. O\u2019Connor, F. Robert, W.G. Devine, A. Selznick, T. Henkel, W.C. Merrick, L.E. Brown, P.V. Baranov, J.A. Porco, J. Pelletier, Rocaglates induce gain-of-function alterations to eIF4A and eIF4F. Cell Rep. 30, 2481-2488.e2485 (2020). https:\/\/doi.org\/10.1016\/j.celrep.2020.02.002","journal-title":"Cell Rep."},{"key":"714_CR81","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(19)30405-X","volume":"20","author":"D Adkins","year":"2019","unstructured":"D. Adkins, J. Ley, P. Neupane, F. Worden, A.G. Sacco, K. Palka, J.E. Grilley-Olson, R. Maggiore, N.N. Salama, K. Trinkaus, B.A. Van Tine, C.E. Steuer, N.F. Saba, P. Oppelt, Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 20, 1295\u20131305 (2019). https:\/\/doi.org\/10.1016\/S1470-2045(19)30405-X","journal-title":"Lancet Oncol."},{"key":"714_CR82","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/hep.31872","volume":"74","author":"J Sheng","year":"2021","unstructured":"J. Sheng, S. Kohno, N. Okada, N. Okahashi, K. Teranishi, F. Matsuda, H. Shimizu, P. Linn, N. Nagatani, M. Yamamura, K. Harada, S.I. Horike, H. Inoue, S. Yano, S. Kumar, S. Kitajima, I. Ajioka, C. Takahashi, Treatment of retinoblastoma 1-Intact hepatocellular carcinoma with cyclin-dependent kinase 4\/6 inhibitor combination therapy. Hepatology 74, 1971\u20131993 (2021). https:\/\/doi.org\/10.1002\/hep.31872","journal-title":"Hepatology"},{"key":"714_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.Cd-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"M. Demaria, M.N. O\u2019Leary, J. Chang, L. Shao, S. Liu, F. Alimirah, K. Koenig, C. Le, N. Mitin, A.M. Deal, S. Alston, E.C. Academia, S. Kilmarx, A. Valdovinos, B. Wang, A. de Bruin, B.K. Kennedy, S. Melov, D. Zhou, N.E. Sharpless, H. Muss, J. Campisi, Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017). https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0241","journal-title":"Cancer Discov."},{"key":"714_CR84","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Y. Zhu, T. Tchkonia, T. Pirtskhalava, A.C. Gower, H. Ding, N. Giorgadze, A.K. Palmer, Y. Ikeno, G.B. Hubbard, M. Lenburg, S.P. O\u2019Hara, N.F. LaRusso, J.D. Miller, C.M. Roos, G.C. Verzosa, N.K. LeBrasseur, J.D. Wren, J.N. Farr, S. Khosla, M.B. Stout, S.J. McGowan, H. Fuhrmann-Stroissnigg, A.U. Gurkar, J. Zhao, D. Colangelo, A. Dorronsoro, Y.Y. Ling, A.S. Barghouthy, D.C. Navarro, T. Sano, P.D. Robbins, L.J. Niedernhofer, J.L. Kirkland, The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644\u2013658 (2015). https:\/\/doi.org\/10.1111\/acel.12344","journal-title":"Aging Cell"},{"key":"714_CR85","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"J. Chang, Y. Wang, L. Shao, R.M. Laberge, M. Demaria, J. Campisi, K. Janakiraman, N.E. Sharpless, S. Ding, W. Feng, Y. Luo, X. Wang, N. Aykin-Burns, K. Krager, U. Ponnappan, M. Hauer-Jensen, A. Meng, D. Zhou, Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016). https:\/\/doi.org\/10.1038\/nm.4010","journal-title":"Nat. Med."},{"key":"714_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.celrep.2017.03.038","volume":"19","author":"OC Olson","year":"2017","unstructured":"O.C. Olson, H. Kim, D.F. Quail, E.A. Foley, J.A. Joyce, Tumor-associated macrophages suppress the cytotoxic activity of antimitotic agents. Cell Rep. 19, 101\u2013113 (2017). https:\/\/doi.org\/10.1016\/j.celrep.2017.03.038","journal-title":"Cell Rep."},{"key":"714_CR87","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1158\/1541-7786.MCR-20-0915","volume":"19","author":"NJ Gadsden","year":"2021","unstructured":"N.J. Gadsden, C.D. Fulcher, D. Li, N. Shrivastava, C. Thomas, J.E. Segall, M.B. Prystowsky, N.F. Schlecht, E. Gavathiotis, T.J. Ow, Palbociclib renders human papilloma virus-negative head and neck squamous cell carcinoma vulnerable to the senolytic agent navitoclax. Mol. Cancer Res. 19, 862\u2013873 (2021). https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0915","journal-title":"Mol. Cancer Res."},{"key":"714_CR88","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jconrel.2020.04.045","volume":"323","author":"I Galiana","year":"2020","unstructured":"I. Galiana, B. Lozano-Torres, M. Sancho, M. Alfonso, A. Bernardos, V. Bisbal, M. Serrano, R. Martinez-Manez, M. Orzaez, Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. J. Control Release 323, 624\u2013634 (2020). https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.045","journal-title":"J. Control Release"},{"key":"714_CR89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-017-0482-3","volume":"10","author":"A Laroche-Clary","year":"2017","unstructured":"A. Laroche-Clary, V. Chaire, M.P. Algeo, M.A. Derieppe, F.L. Loarer, A. Italiano, Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J. Hematol. Oncol. 10, 123 (2017). https:\/\/doi.org\/10.1186\/s13045-017-0482-3","journal-title":"J. Hematol. Oncol."},{"key":"714_CR90","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"S. Goel, M.J. DeCristo, A.C. Watt, H. BrinJones, J. Sceneay, B.B. Li, N. Khan, J.M. Ubellacker, S. Xie, O. Metzger-Filho, J. Hoog, M.J. Ellis, C.X. Ma, S. Ramm, I.E. Krop, E.P. Winer, T.M. Roberts, H.J. Kim, S.S. McAllister, J.J. Zhao, CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475 (2017). https:\/\/doi.org\/10.1038\/nature23465","journal-title":"Nature"},{"key":"714_CR91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Coppe","year":"2010","unstructured":"J.P. Coppe, P.Y. Desprez, A. Krtolica, J. Campisi, The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010). https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102144","journal-title":"Annu. Rev. Pathol."},{"key":"714_CR92","doi-asserted-by":"publisher","first-page":"eabd2712-1","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"N. Patsoukis, Q. Wang, L. Strauss, V.A. Boussiotis, Revisiting the PD-1 pathway. Sci. Adv. 6, eabd2712 (2020). https:\/\/doi.org\/10.1126\/sciadv.abd2712","journal-title":"Sci. Adv."},{"key":"714_CR93","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","volume":"25","author":"J Yu","year":"2019","unstructured":"J. Yu, J. Yan, Q. Guo, Z. Chi, B. Tang, B. Zheng, J. Yu, T. Yin, Z. Cheng, X. Wu, H. Yu, J. Dai, X. Sheng, L. Si, C. Cui, X. Bai, L. Mao, B. Lian, X. Wang, X. Yan, S. Li, L. Zhou, K.T. Flaherty, J. Guo, Y. Kong, Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma. Clin. Cancer Res. 25, 6511\u20136523 (2019). https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0475","journal-title":"Clin. Cancer Res."},{"key":"714_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2021.08.054","author":"HJ Jang","year":"2021","unstructured":"H.J. Jang, C.Y. Truong, E.M. Lo, H.M. Holmes, D. Ramos, M. Ramineni, J.S. Lee, D.Y. Wang, M. Pietropaolo, R.T. Ripley, B.M. Burt, H.S. Lee, Inhibition of CDK4\/6 overcomes primary resistance to PD-1 blockade in malignant mesothelioma. Ann. Thorac. Surg. (2021). https:\/\/doi.org\/10.1016\/j.athoracsur.2021.08.054","journal-title":"Ann. Thorac. Surg."},{"key":"714_CR95","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00262-020-02609-5","volume":"69","author":"Q Long","year":"2020","unstructured":"Q. Long, A.H. Ma, H. Zhang, Z. Cao, R. Xia, T.Y. Lin, G.P. Sonpavde, W.R. de Vere, J. Guo, C.X. Pan, Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunol. Immunother. 69, 2305\u20132317 (2020). https:\/\/doi.org\/10.1007\/s00262-020-02609-5","journal-title":"Cancer Immunol. Immunother."},{"key":"714_CR96","doi-asserted-by":"publisher","unstructured":"C.J. Sherr, D. Beach and G.I. Shapiro, TARGETING CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6, 353\u2013367 (2016) https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0894 %\/ (c)2015 American Association for Cancer Research","DOI":"10.1158\/2159-8290.CD-15-0894"},{"key":"714_CR97","doi-asserted-by":"publisher","unstructured":"L. Wei, B.J. Leibowitz, X. Wang, M. Epperly, J. Greenberger, L. Zhang and J. Yu, Inhibition of CDK4\/6 protects against radiation-induced intestinal injury in mice. J. Clin. Invest 126, 4076\u20134087 (2016). https:\/\/doi.org\/10.1172\/jci88410","DOI":"10.1172\/jci88410"},{"key":"714_CR98","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djs002","volume":"104","author":"PJ Roberts","year":"2012","unstructured":"P.J. Roberts, J.E. Bisi, J.C. Strum, A.J. Combest, D.B. Darr, J.E. Usary, W.C. Zamboni, K.K. Wong, C.M. Perou, N.E. Sharpless, Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. J. Natl. Cancer Inst. 104, 476\u2013487 (2012). https:\/\/doi.org\/10.1093\/jnci\/djs002","journal-title":"J. Natl. Cancer Inst."},{"key":"714_CR99","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1073\/pnas.1424313112","volume":"112","author":"N Pabla","year":"2015","unstructured":"N. Pabla, A.A. Gibson, M. Buege, S.S. Ong, L. Li, S. Hu, G. Du, J.A. Sprowl, A. Vasilyeva, L.J. Janke, E. Schlatter, T. Chen, G. Ciarimboli, A. Sparreboom, Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions. Proc. Natl. Acad. Sci. U. S. A. 112, 5231\u20135236 (2015). https:\/\/doi.org\/10.1073\/pnas.1424313112","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"714_CR100","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12035-018-1098-5","volume":"56","author":"AC Chao","year":"2019","unstructured":"A.C. Chao, C.H. Chen, S.H. Chang, C.T. Huang, W.C. Hwang, D.I. Yang, Id1 and sonic hedgehog mediate cell cycle reentry and apoptosis induced by amyloid beta-peptide in post-mitotic cortical neurons. Mol. Neurobiol. 56, 465\u2013489 (2019). https:\/\/doi.org\/10.1007\/s12035-018-1098-5","journal-title":"Mol. Neurobiol."},{"key":"714_CR101","first-page":"3481","volume":"11","author":"Z Wang","year":"2019","unstructured":"Z. Wang, J. Li, Y. Wang, Q. Liu, Palbociclib improves cardiac dysfunction in diabetic cardiomyopathy by regulating Rb phosphorylation. Am. J. Transl. Res. 11, 3481\u20133489 (2019)","journal-title":"Am. J. Transl. Res."},{"key":"714_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.04.011","author":"V Sundar","year":"2020","unstructured":"V. Sundar, R. Tamizhselvi, Inhibition of Rb phosphorylation leads to H2S-mediated inhibition of NF-kB in acute pancreatitis and associated lung injury in mice. Pancreatology (2020). https:\/\/doi.org\/10.1016\/j.pan.2020.04.011","journal-title":"Pancreatology"},{"key":"714_CR103","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.celrep.2018.07.014","volume":"24","author":"P Nguyen","year":"2018","unstructured":"P. Nguyen, L. Valanejad, A. Cast, M. Wright, J.M. Garcia, H.B. El-Serag, R. Karns, N.A. Timchenko, Elimination of age-associated hepatic steatosis and correction of aging phenotype by inhibition of cdk4-C\/EBP\u03b1-p300 Axis. Cell Rep. 24, 1597\u20131609 (2018). https:\/\/doi.org\/10.1016\/j.celrep.2018.07.014","journal-title":"Cell Rep."},{"key":"714_CR104","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.3390\/ijms22094559","volume":"22","author":"AZ Malikova","year":"2021","unstructured":"A.Z. Malikova, A.S. Shcherbakova, K.A. Konduktorov, A.S. Zemskaya, A.A. Dalina, V.I. Popenko, O.G. Leonova, A.V. Morozov, N.N. Kurochkin, O.A. Smirnova, S.N. Kochetkov, M.V. Kozlov, Pre-senescence induction in hepatoma cells favors hepatitis C virus replication and can be used in exploring antiviral potential of histone deacetylase inhibitors. Int. J. Mol. Sci. 22, 4559 (2021). https:\/\/doi.org\/10.3390\/ijms22094559","journal-title":"Int. J. Mol. Sci."},{"key":"714_CR105","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12967-019-2026-9","volume":"17","author":"YB Hou","year":"2019","unstructured":"Y.B. Hou, K. Ji, Y.T. Sun, L.N. Zhang, J.J. Chen, CDK4\/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation. J. Transl. Med. 17, 276 (2019). https:\/\/doi.org\/10.1186\/s12967-019-2026-9","journal-title":"J. Transl. Med."},{"key":"714_CR106","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1136\/gutjnl-2017-315144","volume":"67","author":"A Chou","year":"2018","unstructured":"A. Chou, D. Froio, A.M. Nagrial, A. Parkin, K.J. Murphy, V.T. Chin, D. Wohl, A. Steinmann, R. Stark, A. Drury, S.N. Walters, C. Vennin, A. Burgess, M. Pinese, L.A. Chantrill, M.J. Cowley, T.J. Molloy, N. Waddell, A. Johns, S.M. Grimmond, D.K. Chang, A.V. Biankin, O.J. Sansom, J.P. Morton, S.T. Grey, T.R. Cox, J. Turchini, J. Samra, S.J. Clarke, P. Timpson, A.J. Gill, M. Pajic, Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 67, 2142\u20132155 (2018). https:\/\/doi.org\/10.1136\/gutjnl-2017-315144","journal-title":"Gut"},{"key":"714_CR107","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12943-020-01210-9","volume":"19","author":"X Jin","year":"2020","unstructured":"X. Jin, L.P. Ge, D.Q. Li, Z.M. Shao, G.H. Di, X.E. Xu, Y.Z. Jiang, LncRNA TROJAN promotes proliferation and resistance to CDK4\/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. Mol. Cancer 19, 87 (2020). https:\/\/doi.org\/10.1186\/s12943-020-01210-9","journal-title":"Mol. Cancer"},{"key":"714_CR108","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41419-019-2098-8","volume":"10","author":"AM Robinson","year":"2019","unstructured":"A.M. Robinson, R. Rathore, N.J. Redlich, D.R. Adkins, T. VanArsdale, B.A. Van Tine, L.S. Michel, Cisplatin exposure causes c-Myc-dependent resistance to CDK4\/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cell Death Dis. 10, 867 (2019). https:\/\/doi.org\/10.1038\/s41419-019-2098-8","journal-title":"Cell Death Dis."},{"key":"714_CR109","doi-asserted-by":"publisher","first-page":"264","DOI":"10.20892\/j.issn.2095-3941.2018.0257","volume":"16","author":"NS Zainal","year":"2019","unstructured":"N.S. Zainal, B.K.B. Lee, Z.W. Wong, I.S. Chin, P.S. Yee, C.P. Gan, K.S. Mun, Z.A.A. Rahman, J.S. Gutkind, V. Patel, S.C. Cheong, Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. Cancer Biol. Med. 16, 264\u2013275 (2019). https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0257","journal-title":"Cancer Biol. Med."},{"key":"714_CR110","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1016\/j.celrep.2019.02.023","volume":"26","author":"L Cornell","year":"2019","unstructured":"L. Cornell, S.A. Wander, T. Visal, N. Wagle, G.I. Shapiro, MicroRNA-mediated suppression of the TGF-\u03b2 pathway confers transmissible and reversible CDK4\/6 inhibitor resistance. Cell Rep. 26, 2667-2680.e2667 (2019). https:\/\/doi.org\/10.1016\/j.celrep.2019.02.023","journal-title":"Cell Rep."},{"key":"714_CR111","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","volume":"24","author":"R de Leeuw","year":"2018","unstructured":"R. de Leeuw, C. McNair, M.J. Schiewer, N.P. Neupane, L.J. Brand, M.A. Augello, Z. Li, L.C. Cheng, A. Yoshida, S.M. Courtney, E.S. Hazard, G. Hardiman, M.H. Hussain, J.A. Diehl, J.M. Drake, W.K. Kelly, K.E. Knudsen, MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancer. Clin. Cancer Res. 24, 4201\u20134214 (2018). https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0410","journal-title":"Clin. Cancer Res."},{"key":"714_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1284-6","author":"S Pancholi","year":"2020","unstructured":"S. Pancholi, R. Ribas, N. Simigdala, E. Schuster, J. Nikitorowicz-Buniak, A. Ressa, Q. Gao, M.F. Leal, A. Bhamra, A. Thornhill, L. Morisset, E. Montaudon, L. Sourd, M. Fitzpatrick, M. Altelaar, S.R. Johnston, E. Marangoni, M. Dowsett, L.A. Martin, Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities. Oncogene (2020). https:\/\/doi.org\/10.1038\/s41388-020-1284-6","journal-title":"Oncogene"},{"key":"714_CR113","doi-asserted-by":"publisher","first-page":"eaaw2106","DOI":"10.1126\/science.aaw2106","volume":"366","author":"KZ Guiley","year":"2019","unstructured":"K.Z. Guiley, J.W. Stevenson, K. Lou, K.J. Barkovich, V. Kumarasamy, T.U. Wijeratne, K.L. Bunch, S. Tripathi, E.S. Knudsen, A.K. Witkiewicz, K.M. Shokat, S.M. Rubin, p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science 366, eaaw2106 (2019). https:\/\/doi.org\/10.1126\/science.aaw2106","journal-title":"Science"},{"key":"714_CR114","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","volume":"11","author":"JY Ge","year":"2020","unstructured":"J.Y. Ge, S. Shu, M. Kwon, B. Jovanovic, K. Murphy, A. Gulvady, A. Fassl, A. Trinh, Y. Kuang, G.A. Heavey, A. Luoma, C. Paweletz, A.R. Thorner, K.W. Wucherpfennig, J. Qi, M. Brown, P. Sicinski, T.O. McDonald, D. Pellman, F. Michor, K. Polyak, Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer. Nat. Commun. 11, 2350 (2020). https:\/\/doi.org\/10.1038\/s41467-020-16170-3","journal-title":"Nat. Commun."},{"key":"714_CR115","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1158\/1541-7786.MCR-18-0188","volume":"17","author":"SRS Gottesman","year":"2019","unstructured":"S.R.S. Gottesman, J. Somma, V. Tsiperson, L. Dresner, U. Govindarajulu, P. Patel, S.W. Blain, Tyrosine phosphorylation of p27Kip1 correlates with palbociclib responsiveness in breast cancer tumor cells grown in explant culture. Mol. Cancer Res. 17, 669\u2013675 (2019). https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0188","journal-title":"Mol. Cancer Res."},{"key":"714_CR116","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4161\/cc.7.7.5637","volume":"7","author":"SW Blain","year":"2008","unstructured":"S.W. Blain, Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 7, 892\u2013898 (2008). https:\/\/doi.org\/10.4161\/cc.7.7.5637","journal-title":"Cell Cycle"},{"key":"714_CR117","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-19-3271","volume":"26","author":"A McCartney","year":"2020","unstructured":"A. McCartney, M. Bonechi, F. De Luca, C. Biagioni, G. Curigliano, E. Moretti, A.M. Minisini, M. Bergqvist, M. Benelli, I. Migliaccio, F. Galardi, E. Risi, I. De Santo, D. Romagnoli, L. Biganzoli, A. Di Leo, L. Malorni, Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with Palbociclib within the TREnd trial. Clin. Cancer Res. 26, 2131\u20132139 (2020). https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3271","journal-title":"Clin. Cancer Res."},{"key":"714_CR118","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1021\/acs.molpharmaceut.9b00540","volume":"16","author":"X Song","year":"2019","unstructured":"X. Song, Q. Gan, X. Zhang, J. Zhang, Synthesis and biological evaluation of novel (99m)Tc-Labeled Palbociclib derivatives targeting cyclin-dependent kinase 4\/6 (CDK4\/6) as potential cancer imaging agents. Mol. Pharm. 16, 4213\u20134222 (2019). https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00540","journal-title":"Mol. Pharm."},{"key":"714_CR119","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jconrel.2020.02.018","volume":"321","author":"YL Su","year":"2020","unstructured":"Y.L. Su, L.W. Kuo, C.H. Hsu, C.S. Chiang, Y.J. Lu, S.J. Chang, S.H. Hu, Rabies virus glycoprotein-amplified hierarchical targeted hybrids capable of magneto-electric penetration delivery to orthotopic brain tumor. J. Control Release 321, 159\u2013173 (2020). https:\/\/doi.org\/10.1016\/j.jconrel.2020.02.018","journal-title":"J. Control Release"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-022-00714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-022-00714-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-022-00714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T22:04:52Z","timestamp":1671228292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-022-00714-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1007\/s13402-022-00714-4","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]},"assertion":[{"value":"1 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}